Stephen J. Schueler, M.D.

Overview Incidence Risk Factors Symptoms Evaluation Treatment questions for doctor specialist Home Care diet warning signs Prevention vaccine Outlook Complications Transmission Anatomy

Hepatitis A Vaccine

Hepatitis A vaccine can prevent hepatitis A.

Common brand names for this vaccine include:

  • Avaxim
  • Epaxal
  • Havrix
  • Hepatyrix
  • Vaqta Paediatric
  • ViATIM

Indications for Hepatitis A Vaccine
  • Persons 2 years of age and older traveling to or working in countries with high or intermediate prevalence of hepatitis A, such as those located in Central or South America, the Caribbean, Mexico, Asia (except Japan), Africa, and eastern Europe.
  • Children and adolescents who live in states or communities where routine vaccination has been recommended.
  • Men who have sex with men.
  • Persons who use street drugs.
  • Persons with chronic liver disease.
  • Persons who are treated with clotting factor concentrates.
  • Those traveling to an area where hepatitis A is common.

Anyone who moderately or severely ill at the time the shot is scheduled should probably wait until they recover. Ask your doctor or nurse. People with a mild illness can usually get the vaccine.

Primary immunization for adults consists of single dose. Primary immunization for children (2 to 18 years of age) consists of 2 doses, given 1 month apart.

Side Effects
Getting hepatitis A vaccine is much safer than getting the disease.

Mild problems:

Serious problems:

Continue to Hepatitis A Outlook

Last Updated: Apr 30, 2008 References
Authors: Stephen J. Schueler, MD; John H. Beckett, MD; D. Scott Gettings, MD
Copyright DSHI Systems, Inc. Powered by: FreeMD - Your Virtual Doctor

PubMed Hepatitis A References
  1. Centers for Disease Control and Prevention (CDC). Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis--United States, 2002-2004. MMWR Morb Mortal Wkly Rep. 2005 May 13;54(18):453-6. [15889006]
  2. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004 Dec;132(6):1005-22. [15635957]
  3. Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs. 2003;63(23):2625-49. [14636084]
  4. Oncu S, Oncu S, Sakarya S. Hepatitis A and B seropositivity among medical students. Health Policy. 2005 Sep 28;74(1):39-45. [16098410]
  5. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat. 2005 Jan;12(1):101-5. [15655056]
  6. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005 Jul 13;294(2):194-201. [1601459]
FreeMD is provided for information purposes only and should not be used as a substitute for evaluation and treatment by a physician. Please review our terms of use.